Results 201 to 210 of about 42,820 (244)

Irreversible inhibition of glutamate decarboxylase by .alpha.-(fluoromethyl)glutamic acid

Biochemistry, 1981
alpha-(Fluoromethyl)glutamic acid (FMG) was synthesized and shown to be an active site directed irreversible inhibitor of glutamate decarboxylase (EC 4.1.1.15) from Escherichia coli. The KI for the active enantiomer is 1.4 microM, and the kinh = 5.9 X 10(-3) s-1.
D, Kuo, R R, Rando
openaire   +2 more sources

Effect of phosphonic analogues of glutamic acid on glutamate decarboxylase

Experientia, 1985
Among the phosphonic analogues of glutamic acid, only 4-amino-4-phosphono butyric acid, the compound which shows the highest affinity for pyridoxal phosphate, inhibits competitively both Escherichia coli and rat brain glutamate decarboxylases. Phosphinothricin, 2-amino-4-(methylphosphino)butyric acid, is a strong inhibitor of the mammalian enzyme.
A M, Lacoste, S, Mansour, A, Cassaigne, E, Neuzil   +3 more
openaire   +2 more sources

Spectrophotometric assay of l-glutamic acid decarboxylase

Analytical Biochemistry, 1970
Abstract A spectrophotometric method has been developed for the measurement of glutamic acid decarboxylase activity and applied to the kinetic study of the enzyme from Clostridium perfringens . The results are compared with those obtained by manometric method.
openaire   +2 more sources

The application of glutamic acid α-decarboxylase for the valorization of glutamic acid

Green Chemistry, 2009
Glutamic acid is an important constituent of waste streams from biofuels production. It is an interesting starting material for the synthesis of nitrogen containing bulk chemicals, thereby decreasing the dependency on fossil fuels. On the pathway from glutamic acid to a range of molecules, the decarboxylation of glutamic acid to γ-aminobutyric acid ...
Lammens, T.M., De Biase, Daniela, Franssen, M.C.R., Scott, E.L., Sanders, J.P.M.   +4 more
openaire   +1 more source

Glutamic Acid Decarboxylase Autoantibody Syndrome Presenting as Schizophrenia

The Neurologist, 2012
Glutamic acid decarboxylase (GAD) is the rate-limiting enzyme converting glutamate into γ-aminobutyric acid. Impaired GAD function can alter motor, cognitive, and behavioral function. Anti-GAD antibodies (GADAbs) can cause several neurological disorders.
Souhel, Najjar, Daniel, Pearlman, David, Zagzag, John, Golfinos, Orrin, Devinsky   +4 more
openaire   +2 more sources

Anti-glutamic Acid Decarboxylase Limbic Encephalitis

2017
Anti-glutamic acid decarboxylase antibody-associated limbic encephalitis (AGADE) is a nonclassic antibody-mediated disease that typically manifests with psychiatric symptoms and seizures in the pediatric population. Glutamic acid decarboxylase (GAD) is highly expressed in the hippocampus and pancreas, which is thought to explain why AGADE tends to also
Robert Rudock, Jason Helis, Soe S. Mar
openaire   +1 more source

Taurine, Cysteinesulfinic Acid Decarboxylase and Glutamic Acid in Brain

1982
Despite the intensive studies of many investigators the role of taurine in mammals, other than as a component of taurocholate, is still unknown (2,3,11). The difficulty in assigning a function to taurine results from the large number of organs, actions and conditions with which the compound has been associated, such as neurotransmission (18,29 ...
openaire   +2 more sources

GLUTAMIC-ACID DECARBOXYLASE IN SCHIZOPHRENIA

The Lancet, 1978
E D, Bird, E G, Spokes, J, Barnes, A V, Mackay, L L, Iversen, M, Shepherd   +5 more
openaire   +2 more sources

[Gamma-aminobutyric acid and glutamate decarboxylase].

Bratislavske lekarske listy, 1994
Gamma-aminobutyric acid (GABA) is the main inhibitory neurotransmitter in the CNS, taking part in processes which are now relatively well understood but also in processes which are remarkable progress has been achieved. The most thoroughly studied field of GABA operation is its role of inhibitory neurotransmitter realized through the mediation of GABA ...
openaire   +1 more source

A MODIFIED GLUTAMIC ACID DECARBOXYLASE (GAD)

1997
A modified GAD especially characterized by a substantially preserved immunogenicity in connection with diabetes compared with a non-modified GAD and a reduced or non-existent effectivity in connection with a GABA-synthesis. The invention relates also to a method for manufacturing a modified GAD, a method for supplying a modified GAD, nucleotide ...
FALORNI, Alberto, Lernmark Ake, Robertson John, Essen Moeller Anders   +3 more
openaire   +1 more source